

# BMS 433796

Catalog No: tcsc0661



## Available Sizes

**Size:** 1mg

**Size:** 5mg

**Size:** 10mg



## Specifications

**CAS No:**

935525-13-6

**Formula:**

$C_{19}H_{16}F_2N_4O_4$

**Pathway:**

Stem Cell/Wnt;Neuronal Signaling

**Target:**

$\gamma$ -secretase; $\gamma$ -secretase

**Purity / Grade:**

>98%

**Solubility:**

10 mM in DMSO

**Observed Molecular Weight:**

402.35

## Product Description


BMS 433796 is a  **$\gamma$ -secretase** inhibitor with **A $\beta$**  lowering activity in a transgenic mouse model of Alzheimer's disease.

IC50 & Target:  $\gamma$ -secretase<sup>[1]</sup>

***In Vitro:***

BMS-433796 cause a concentration-dependent decrease in [<sup>3</sup>H]IN973 binding, with IC<sub>50</sub> value of 1.2 nM, very similar to the IC<sub>50</sub> values for inhibition of Aβ<sub>40</sub> in human embryonic kidney cells overexpressing the Swedish mutation of APP of 0.8 nM, respectively, and for inhibition of Aβ<sub>42</sub> of 0.4 nM, respectively<sup>[2]</sup>.

**In Vivo:** BMS 433796 is characterized in pharmacokinetic studies in male Sprague-Dawley rats. Following a 10-min intravenous infusion at 2.3 μmol/kg in PEG-400, the total body clearance of 40 is 5.2±0.82 mL/min/kg (means±SEM; n=3), indicating low clearance. The apparent terminal elimination half-life is 4.6±0.48 h. Oral administration of a PEG-400 suspension at 35 μmol/kg shows an oral bioavailability of 31% with prolonged absorption. BMS 433796 has satisfactory metabolic stability in human liver microsomal preparations and is not an inhibitor of human CYPs (IC<sub>50</sub>>100 μM)<sup>[1]</sup>. Brain Aβ<sub>40</sub> is reduced as a result of administering BMS-433796 in a dose-dependent manner, with ED<sub>50</sub> value of 2.4 mg/kg, respectively<sup>[2]</sup>.



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!